Application of Dipsacus asper saponin B in the preparation of a drug for treating depression-related mental disorders
By using Dipsacus saponin B to prepare a drug that inhibits Th17 cell-mediated neuroinflammation, the high prevalence of chronic post-stress depression has been addressed, providing an effective treatment and prevention method for depression.
Patent Information
- Application Number
- CN202310341402.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-03
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-04-03
AI Technical Summary
Current technologies have failed to effectively suppress Th17 cell-mediated neuroinflammation, leading to a high prevalence, disability, and mortality rate of chronic post-stress depression, and there is a lack of effective prevention and treatment methods.
Using Dipsacus saponin B as the active ingredient, this drug is used to intervene in neuroinflammation caused by chronic stress, inhibit the level of Th17 cell-related inflammatory factors, protect the blood-brain barrier, and improve depression-related mental disorders.
Dipsacin B significantly improves depressive behavior induced by chronic restraint stress, reduces the level of Th17 cell-related cytokines, protects the blood-brain barrier, and inhibits neuroinflammation, providing a new drug approach for the prevention and treatment of depression.
Smart Images

Figure CN116211878B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the use of dipsaponin B in preparing a medicine for preventing or treating mental illness, and specifically relates to the use of dipsaponin B in preparing a medicine for treating depression-related mental disorders. Background Art
[0002] At present, the current situation of depression in my country is severe, with the number of patients exceeding 95 million. In addition to the high prevalence, there are also high disability and mortality rates, which has brought a serious burden to society. Most of the incidence of depression is closely related to persistent chronic stress stimulation. Therefore, the prevention and treatment of such chronic post-stress mental disorders is a major frontier issue in current national scientific research. For this type of mental disorder, early prevention and intervention can effectively reduce the risk of disease or relieve symptoms. Under the influence of chronic stress, the level of inflammatory factors in the body increases, the neuroimmune response is overactivated, and there is damage to the blood-brain barrier and the aggregation of peripheral immune cells. Among them, neuroinflammation mediated by Th17 cells entering the central nervous system is an important pathological mechanism of chronic post-stress depression. Therefore, how to inhibit Th17 cell-mediated neuroinflammation is a difficult problem that needs to be solved urgently.
[0003] Dipsacoside B (DB) is one of the important pentacyclic triterpenoid saponins in Dipsacus. Pentacyclic triterpenoid saponins are a class of compounds with novel chemical structures and complex stereostructures. They have multiple biological activities. Some studies have reported the therapeutic effect of Dipsacoside B on cardiovascular diseases, but there has been no report on its use in the treatment of depression-related mental illnesses.
[0004] Dipsacus root saponin B is an important compound that I have been paying attention to for a long time. In previous studies, we discovered for the first time that Dipsacus root saponin B has a significant improvement effect on the depressive behavior of mice caused by chronic restraint stress, and can improve central inflammation caused by chronic stress and reduce the levels of Th17 cell-related cytokines. At present, no related research has been reported in this field. Developing it into a drug for the treatment of depression-related mental disorders has extremely high potential value and significance. Summary of the invention
[0005] The purpose of the present invention is to solve at least one of the technical problems existing in the prior art. To this end, the present invention provides a new use of Dipsacus saponin B in pharmaceutical manufacturing, specifically relates to the use of Dipsacus saponin B in the preparation of drugs for preventing or treating mental illness.
[0006] The chemical structural formula of the radix dipsaponin B of the present invention is shown in the accompanying drawings of the specification. Figure 1 As shown: (molecular formula C53H86O22, molecular weight 1075.44).
[0007] In the study, the inventors adopted a 28-day chronic restraint mouse model, and evaluated the improvement effect of Dipsacus asper saponin B on the depressive behavior of mice caused by chronic restraint stress through behavioral tests such as sugar water preference test, tail suspension test, open field test, novel environment feeding inhibition test and forced swimming test; the results showed that the compound Dipsacus asper saponin B can effectively improve the depressive behavior caused by chronic restraint stress; the results of detecting blood-brain barrier-related proteins (tight junction protein Cluadin-5) in the brain by protein immunoblotting showed that Dipsacus asper saponin B can reduce the decrease in tight junction protein expression caused by chronic restraint stress and protect the blood-brain barrier structure; the morphological changes of glial cells in the brain were observed by immunofluorescence, and the results showed that Dipsacus asper saponin B can effectively inhibit glial cell activation and thus inhibit the occurrence of neuroinflammation; the levels of Th17 cell-related inflammatory factors in the brain were detected by enzyme-linked immunosorbent assay, and the results showed that Dipsacus asper saponin B can significantly inhibit the increase in the levels of Th17 cell-related inflammatory factors, that is, the use of the compound Dipsacus asper saponin B of the present invention in the preparation of drugs for the prevention and treatment of depression-related mental disorders.
[0008] Preferably, the depression-related mental illness is a mental illness associated with Th17 cell-mediated neuroinflammation.
[0009] It can be seen from the above experimental results that the in vivo pharmacological experiments in the embodiments of the present invention show that Chuanxiong Saponin B participates in the regulation process of central nervous system inflammatory response and has the effect of inhibiting the level of inflammatory factors in the brain. Drugs for preventing and treating neuroinflammation can be further prepared, and the drugs include Chuanxiong Saponin B or a pharmaceutically acceptable salt thereof.
[0010] Therefore, another object of the present invention is to provide a medicine prepared from Dipsacus asper saponin B for preventing and treating neuroinflammation.
[0011] Preferably, the drug further comprises a pharmaceutically acceptable carrier. Further, the pharmaceutically acceptable carrier comprises one or more solids, semisolids or liquids.
[0012] Preferably, the drug is a pharmaceutically acceptable preparation. Further, the pharmaceutically acceptable preparation includes tablets, capsules, injections, granules, and pills.
[0013] The present invention is further illustrated by way of examples, but the present invention is not limited to the scope of the examples. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 is the chemical structural formula of dipsaponin B of the present invention;
[0015] Figure 2 This is a schematic diagram of the results of the sugar water preference experiment of the first embodiment of the present invention;
[0016] Figure 3 This is a schematic diagram of the results of a novel environment feeding inhibition experiment in the first embodiment of the present invention;
[0017] Figure 4 This is a schematic diagram of the results of a forced swimming experiment according to the first embodiment of the present invention;
[0018] Figure 5 This is a schematic diagram of the results of the tail suspension experiment of the first embodiment of the present invention;
[0019] Figure 6 This is a schematic diagram of the total distance animals move in an open field experiment according to the first embodiment of the present invention;
[0020] Figure 7 This is a schematic diagram of the percentage of time spent in the central area of an animal's movement in an open field experiment according to the first embodiment of the present invention;
[0021] Figure 8 This is a schematic diagram of the movement trajectory of animals in an open field experiment according to the first embodiment of the present invention;
[0022] Fig. 9 This is a schematic diagram of the effect of Dipsacus asper saponin B on the expression of tight junction protein Claudin-5 in the brain according to the second embodiment of the present invention;
[0023] Fig.10 This is a schematic diagram of representative immunofluorescence images of microglial Iba1 and neuronal NeuN in the third embodiment of the present invention;
[0024] Fig.11 This is a statistical diagram of Iba1 positive staining in the third embodiment of the present invention;
[0025] Fig.12 This is a diagram of microglial sholl analysis in the third embodiment of the present invention;
[0026] Fig.13 This is a schematic diagram of the fourth embodiment of the present invention, that Dipsacus asper saponin B reduces the expression of TGF-β, a Th17-related inflammatory factor level;
[0027] Fig.14 This is a schematic diagram of the fourth embodiment of the present invention in which Dipsacus asper saponin B reduces the expression of IL-17A, a Th17-related inflammatory factor level. DETAILED DESCRIPTION
[0028] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0029] Embodiment 1:
[0030] See also Figure 2-8 , which is the first embodiment of the present invention, and this embodiment is a behavioral test of the effect of Dipsacus asper saponin B on improving depressive behavior caused by chronic restraint stress.
[0031] Healthy male C57BL / 6 mice weighing 20-22g were selected. They were divided into normal control group (control), chronic restraint group (model), DB low-dose group (10mg / kg), DB medium-dose group (30mg / kg), DB high-dose group (100mg / kg), and positive drug control fluoxetine group (10mg / kg), with 15 mice in each group. The drug group was intraperitoneally injected with drugs, and the control and model groups were intraperitoneally injected with equal volumes of saline. Therapeutic administration began on the 14th day of CRS modeling and continued until the end of all experiments. Chronic restraint is a widely used animal mental stress model. Mice were placed in transparent acrylic tubes with several vents for behavioral restriction for 6 hours / day / mouse. They were fasted and deprived of water during the restraint period. The control group was also fasted and deprived of water during this period. They were restrained for 28 days. Behavioral evaluation includes: (1) Sugar water preference experiment: used to test the anhedonia of animals. Before the test, all animals received 3 days of adaptation training to freely choose drinking water and 2% sucrose water. The animals' preference for sucrose water and drinking water was used as a baseline. Sucrose water and drinking water were placed on the animal cage 24 hours before the test. The 24-hour fluid consumption was recorded, and the formula for calculating sucrose water preference was: Sucrose preference (%) = sucrose intake / (sucrose intake + water intake) × 100% (2) Forced swimming test: used to test the behavioral despair of animals. On the day of the test, the mice were placed in a cylindrical plexiglass bucket with a diameter of 15 cm and a height of 25 cm, with a camera on the side for recording. The water temperature was 23–25℃ and the water surface height was 40 cm. The water was changed before each mouse was tested. The forced swimming time lasted for 6 minutes, and the mice were immediately returned to the cage after the test. The immobility time of the mice was analyzed by software, and floating, upright immobility, or small movements of keeping the head above the water surface were recorded as immobility. The immobility time data within the last 5 minutes were collected. (3) Novel environment food intake inhibition test: The mice were fasted for 24 hours (but not water), and placed in a corner of a novelty inhibition food intake box with an open top, facing the box wall. The bottom of the box was covered with 2 cm thick sawdust, and 15 food pellets of the same size were placed in the center. The latency of the mice to start eating within 5 minutes was calculated at the same time. (4) Tail suspension test: Stick adhesive tape 2 cm from the end of the mouse's tail, clamp the tape with a clip, and make the mouse hang upside down with its head about 5 cm from the bottom of the tail suspension box. Observe for 6 minutes and record the cumulative immobility time in the last 4 minutes. The criterion for judging immobility is that the animal stops struggling, the body is in a vertical upside-down state, and remains motionless. (5) Open field test: After the mouse is placed in the test box and adapted for 5 minutes, the test begins. Observe and count the activity of the animal within 10 minutes. The software calculates the ratio of the total time spent in the central area / peripheral area. For results, please refer to the attached figure in the instruction manual. Figure 2-Figure 8 .
[0032] The results showed that Dipsacus root saponin B can effectively improve the decreased sugar preference caused by chronic restraint stress ( Figure 2 ), shortening the feeding latency in novel environment feeding inhibition ( Figure 3 ), indicating that it can inhibit the anhedonia in depressive-like behavior and reduce the immobility time of animals in the tail suspension test and forced swimming test ( Figure 4-5 ), inhibiting behavioral despair; under the premise that there was no significant difference in total movement distance (P>0.05), the treatment groups of Dipsacus asper saponin B increased the exploration time of the central area in the open field test ( Figure 8 ). From the overall behavioral perspective, it can be concluded that the compound Dipsacus asper saponin B can effectively improve the depressive behavior caused by chronic restraint stress.
[0033] Embodiment 2:
[0034] See also Fig. 9 , which is the second embodiment of the present invention, and this embodiment is the effect of Chuanxiong saponin B on protecting the blood-brain barrier.
[0035] Blood-brain barrier damage is an important link in the formation of excessive neuroinflammatory response after chronic stress stimulation. Western blotting was used to detect the expression of blood-brain barrier-related proteins (tight junction protein Cluadin-5) in the brain. After modeling and drug administration, the mouse prefrontal cortex was taken, washed three times with pre-cooled PBS, and 100 μL (100:1) of a mixture of RIPA lysis buffer and PMSF was added and placed in a tissue grinder for low-temperature grinding for 20 minutes, and the protein was collected. Centrifuged at 4°C, 13000r / min for 15 minutes, and the supernatant was collected. The sample was boiled at 100°C for 10 minutes to denature it. According to the molecular weight of the protein, 6-12% polyacrylamide gels of different difficulty were prepared for electrophoresis separation (80V for concentrated gel and 120V for separation gel), 0.22μm PVDF membrane was wet-transferred at 200mA for 120min, blocked with 5% skim milk for 1h, added with primary antibody and incubated at 4℃ overnight, washed with TBST 4 times, 15min each time, added with corresponding secondary antibody and incubated at room temperature for 1h, then washed with TBST 4 times, 15min each time, developed with chemiluminescence development, and grayscale analysis was performed after the results were obtained from three independent experiments. For representative band results and analysis results, please refer to the attached figure of the instruction manual. Fig. 9 .
[0036] The experimental results showed that chronic restraint stress could lead to down-regulation of Cluadin5 expression, indicating that the blood-brain barrier structure was damaged, while different doses of Dipsacus saponin B could increase the expression of Cluadin5 (P<0.05), indicating that Dipsacus saponin B had a protective effect on the blood-brain barrier.
[0037] Embodiment 3:
[0038] See also Figure 10-12, which is the third embodiment of the present invention, and this embodiment is that Chuanxiong saponin B inhibits the activation of microglia in the brain and thus reduces neuroinflammation.
[0039] Immunofluorescence was used to detect the activation status of microglia in the brain. The brain tissue was dehydrated after being fixed, and then embedded with a frozen section embedding agent and placed under a freezing microtome for sectioning. The brain slices were placed in a well plate and stored with PBS: glycerol = 1:1. When staining the slices, the brain slices were selected with a slice brush, incubated with the relevant primary antibody overnight, rinsed, and incubated with the secondary antibody at room temperature for 2 hours. The patch was placed under laser confocal microtome for photography.
[0040] Microglial activation often triggers a series of neuroinflammatory reactions. The experimental results show that chronic restraint stress can lead to an increase in the number of microglia in the prefrontal cortex of mice, an increase in pseudopod branches, and an activated state. The interventional treatment of Dipsacus asper saponin B can significantly improve the activation state and reduce the number of cells. From the results of Sholl Analysis morphological analysis, it can be seen that chronic restraint stress (model group) leads to an increase in microglial branches, while Dipsacus asper saponin B can effectively reduce the number of pseudopod branches within a certain range and inhibit cell activation. The above cell morphological analysis results show that Dipsacus asper saponin B can effectively inhibit microglial activation caused by chronic restraint stress.
[0041] Embodiment 4:
[0042] See also Figure 13-14 , which is the second embodiment of the present invention, and this embodiment is that Chuanxiong saponin B inhibits the expression level of Th17 related inflammatory factors in the brain.
[0043] Enzyme-linked immunosorbent assay was used to detect the expression of Th17-related inflammatory factors (TGF-β and IL-17A) in the brain. After modeling and drug administration, the mouse prefrontal cortex was taken, washed three times with pre-cooled PBS, and 100 μL (100:1) of a mixture of RIPA lysis buffer and PMSF was added and placed in a tissue grinder for low-temperature grinding for 20 minutes, and the protein was collected. Centrifuged at 4°C, 13000r / min for 15 minutes, and the supernatant was collected. After the sample was diluted 100 times, it was tested according to the instructions of the kit provided by Shanghai Biyuntian Biological Company. After the kit was equilibrated at room temperature for 20 minutes, the sample or the diluted standard of different concentrations was added to the corresponding well at 100 μL per well, and one duplicate well was set for each well. At the same time, a background correction well, that is, a blank well, was set up, and the setting method was that only TMB solution and stop solution were added to the well. Seal the reaction wells with a sealing film, incubate at room temperature for 120 minutes, wash the plate 5 times, and pat dry on thick absorbent paper for the last time; add 100 μL of biotinylated antibody to each well, incubate at room temperature for 60 minutes after sealing, and wash the plate 5 times; add 100 μL of horseradish peroxidase-labeled streptavidin to each well, incubate at room temperature in the dark for 20 minutes, and wash the plate 5 times; add 100 μL of TMB colorimetric solution to each well, incubate at room temperature in the dark for 20 minutes; add 50 μL of stop solution to each well, mix well, and immediately measure the A value at 450 nm. Draw a standard curve based on the standard concentration and A value, and calculate the sample concentration based on the sample A value and the standard curve.
[0044] Embodiment 5:
[0045] The fifth embodiment of the present invention is based on the above four embodiments. Experimental results show that chronic restraint stress causes a significant increase in the levels of inflammatory factors such as IL-17 and TGF-β in the mouse brain, while Dipsacus asper saponin B can effectively reduce the levels of the above inflammatory factors, indicating that Dipsacus asper saponin B has a significant inhibitory effect on related neuroinflammatory reactions mediated by Th17 cells.
Claims
1. Use of Dipsacus asper saponin B in the preparation of a drug for treating depression-related mental disorders, wherein the depression-related mental disorders are mental disorders associated with Th17 cell-mediated neuroinflammation.
2. The use of a dipsaponin B according to claim 1 in the preparation of a drug for treating depression-related mental disorders, characterized in that: The medicine is a medicine for preventing and treating neuroinflammation, and the medicine comprises chuanxiong saponin B or a pharmaceutically acceptable salt thereof.
3. The use of a dipsaponin B according to claim 1 in the preparation of a drug for treating depression-related mental disorders, characterized in that: The medicament further comprises a pharmaceutically acceptable carrier, which includes one or more solid, semi-solid or liquid.
4. The use of a dipsaponin B according to claim 1 in the preparation of a drug for treating depression-related mental disorders, characterized in that: The drug is a pharmaceutically acceptable preparation.
5. The use of a dipsaponin B according to claim 4 in the preparation of a drug for treating depression-related mental disorders, characterized in that: The pharmaceutically acceptable preparations include tablets, capsules, injections, granules, and pills.
Citation Information
Patent Citations
Application of neuroprotective effect of asperosaponin VI to treatment of depression
CN110693894A
Applications of dipsacoside B in preparation of drugs for preventing and treating vascular diseases
CN112641794A
Composition for improvement of vascular endothelial dysfunction
KR1020180035538A
